Methodology

All entries for: Cabaletta Bio Inc.

December 10, 2025

Cabaletta Bio Inc.

Orphan Drug Designation

FDA orphan drug designation: treatment of myasthenia gravis

Disease Area: Rare Diseases
Source
Source
Scroll to Top